New Research Reveals Healthcare Leaders Who Unite Financial and Clinical Data Recover Millions in Previously Missed Revenue

Rhea-AI Summary

Waystar (Nasdaq: WAY) released its 2026 State of the Mid‑Revenue Cycle report, highlighting strong demand for a single AI platform linking mid-cycle to final claim. A survey of 50 leaders found 86% lack true integration, 82% struggle with changing payer policies, and 56% are dissatisfied with denial prediction.

Waystar’s client data analysis shows integrated workflows can deliver $2.17 million in incremental reimbursement and up to $3 million in additional revenue per 10,000 cases, improve PSI‑90 quality scores by 8.4 points, cut medical-necessity denials below 2%, and lift observation-to-inpatient conversions by 13%.

News Market Reaction – WAY

+1.00%

2 alerts

+1.00% Session close to close

+6.6% Peak Tracked

$3.68B Market Cap

1.72K Volume

In the Jun 9 session, WAY gained 1.00%, reflecting a mild positive market reaction. Argus tracked a peak move of +6.6% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights how connecting financial and clinical data in the mid-revenue cycle can...

Analysis

This announcement highlights how connecting financial and clinical data in the mid-revenue cycle can unlock substantial value, including $2.17M incremental reimbursement and up to $3M additional revenue per 10,000 cases, alongside an 8.4-point PSI-90 improvement. Set against prior earnings strength and AI recognition, it reinforces a consistent automation narrative. Investors may watch adoption levels of these AI workflows, future quantified client outcomes, and how such performance translates into reported revenue and margin trends.

Key Figures

Leaders surveyed: 50 leaders Lack integration: 86% Policy pace concern: 82% +5 more

8 metrics

Leaders surveyed 50 leaders Spring 2026 market survey sample size

Lack integration 86% Leaders lacking true integration between mid-cycle and final claim systems

Policy pace concern 82% Leaders who cannot keep pace with payer clinical policy changes

Denial prevention dissatisfaction 56% Leaders not satisfied with ability to predict/prevent denials

CDI impact increase 87% Increase in CDI program impact with integrated workflows

Incremental reimbursement $2.17 million Incremental reimbursement per 10,000 discharges from CDI

PSI-90 improvement 8.4 points Average improvement in PSI-90 scores with CDI

Incremental revenue $3 million Incremental revenue per 10,000 admissions from anomaly detection

Historical Context

5 past events · Latest: May 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 20	Conference appearance	Neutral	-2.2%	CEO scheduled to speak at William Blair growth stock conference.
May 19	Share repurchase plan	Positive	+7.2%	Board authorized up to $200M common stock repurchases.
May 05	Industry recognition	Positive	-3.5%	Named to TIME100 with AI impact award and AltitudeAI metrics.
Apr 29	Earnings results	Positive	-15.4%	Q1 2026 beat-style metrics with strong growth and guidance range.
Apr 08	Earnings date set	Neutral	-0.9%	Announced timing and webcast details for Q1 2026 call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

WAY has often seen negative reactions to seemingly positive milestones (strong Q1 results, TIME100 recognition) while capital return news like the share repurchase drew a positive response, suggesting investors focus heavily on valuation and capital allocation.

Recent Company History

Over the past few months, WAY has reported several notable developments. Q1 2026 results on Apr 29 showed strong growth, yet shares fell 15.41%. Recognition in the TIME100 list on May 5 also coincided with a 3.49% drop. By contrast, the $200M share repurchase authorization on May 19 produced a 7.24% gain. Conference and event announcements in early April and late May drew only modest declines, framing today’s operational AI-focused report against a backdrop of mixed reactions to prior news.

Key Terms

clinical documentation integrity, utilization management, patient safety indicator composite (psi-90), observation-to-inpatient conversion, +4 more

8 terms

clinical documentation integrity medical

"Waystar Clinical Documentation Integrity delivers 3x greater financial impact..."

Clinical documentation integrity is the practice of making sure medical records accurately and completely reflect a patient’s diagnosis, treatment and outcomes, like keeping a precise blueprint for a building. It matters to investors because clear, consistent records affect how much healthcare providers are paid, their legal and regulatory risk, and reported quality measures, all of which influence revenue, cash flow and reputation.

utilization management medical

"Waystar Utilization Management increases observation-to-inpatient conversion rates..."

Utilization management is the process health insurers and providers use to review and approve medical services, tests, and treatments to make sure they are necessary, appropriate, and cost-effective. For investors, it matters because these reviews influence how often care is paid for, affect healthcare providers’ revenues and drug or device sales, and can change costs and demand—like a gatekeeper deciding which requests move forward and which do not.

patient safety indicator composite (psi-90) medical

"and improve Patient Safety Indicator Composite (PSI-90) scores by an average..."

A patient safety indicator composite (PSI-90) is a single score that combines several hospital safety measures—such as surgical complications, infections and other preventable harms—into one overall rating of how often patients experience avoidable harm. Investors watch this score because it can influence reimbursement, public reputation and legal or regulatory risk much like a car’s crash-test rating affects resale value and insurance costs, so a poor PSI-90 can signal higher costs or lower demand.

observation-to-inpatient conversion medical

"increase observation-to-inpatient conversion rates by 13%, captures more revenue..."

Observation-to-inpatient conversion is when a patient who was initially placed under short-term monitoring is later formally admitted to the hospital as an inpatient. For investors, this shift matters because it commonly changes how the stay is billed and reimbursed, affects reported patient volumes and average length of stay, and can influence hospital revenue and margins—similar to a trial purchase turning into a full sale for a retailer.

denial rates medical

"and reduce medical-necessity denial rates to less than 2%, demonstrating the value..."

Denial rates measure the share of requests—such as insurance claims, reimbursement requests, loan applications or regulatory filings—that are rejected by the payer, lender or authority. For investors, rising denial rates act like a leaking pipe: they reduce expected cash inflows, signal operational or compliance problems, and can raise costs for appeals or rework, so they directly affect revenue reliability and profit margins.

revenue cycle technical

"These results reflect the power of the autonomous revenue cycle, connecting..."

The revenue cycle is the end-to-end process a business uses to record a sale, issue a bill, and collect payment — essentially the pipeline that turns products or services into cash. Investors watch it because a smooth, fast cycle means steady cash flow and lower risk of unpaid bills, while delays or errors can signal hidden costs, weakening profitability and increasing uncertainty about future earnings, much like a clogged pipe slowing water to a tap.

autonomous revenue cycle technical

"These results reflect the power of the autonomous revenue cycle, connecting..."

An autonomous revenue cycle is a largely self-running system that handles the full sequence of billing, insurance claims, payments and follow-up tasks for healthcare services using software and automation. For investors it matters because it can cut labor costs, speed up cash collection, reduce billing errors and lower compliance risk—similar to replacing a slow, manual checkout line with an automated, faster conveyor belt that needs fewer attendants.

ai-powered platform technical

"a single AI-powered platform connecting the mid-cycle to the final claim..."

An ai-powered platform is a software system that uses artificial intelligence—computer algorithms that learn from data—to automate tasks, spot patterns, and make predictions or recommendations. For investors, it matters because the platform can boost a company’s efficiency, lower costs, enable new products or revenue streams, and scale operations faster—think of it as a smart assistant or autopilot that can improve performance and affect future profits and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Healthcare leaders show unanimous interest in a single AI-powered platform connecting the mid-cycle to the final claim — yet 86% are still leaving revenue on the table

LEHI, Utah and LOUISVILLE, Ky., June 9, 2026 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today released The State of the Mid-Revenue Cycle report. The new research found unanimous interest among healthcare finance leaders in a single AI-powered platform connecting the mid-cycle to the final claim, yet 86% lack true integration between those systems, relying instead on manual data transfers or disconnected solutions across the revenue cycle.

The spring 2026 market survey of 50 healthcare finance, revenue cycle, and mid-cycle leaders underscores the pressure behind those numbers: 82% say they cannot keep pace with rapidly changing payer clinical policies, and 56% are not satisfied with their ability to predict and prevent denials before a claim is generated. The accompanying analysis of data from hundreds of hospitals using Waystar's platform demonstrates how a connected, AI-powered mid-cycle can deliver millions of dollars of incremental revenue, improve quality scores, and reduce denial risk. 

"The mid-cycle is the critical intersection where financial and clinical data converge to improve clarity and performance," said Matt Hawkins, Chief Executive Officer of Waystar. "Our research shows that when providers connect this data across previously siloed workflows, they recover millions in revenue that would otherwise be lost, improve operational efficiency, and strengthen ROI. These results reflect the power of the autonomous revenue cycle, connecting intelligence with action across the platform."

The analysis of Waystar client performance further quantifies the impact of a connected, AI-powered mid-cycle enabled by the Waystar platform:

• Waystar Clinical Documentation Integrity delivers 3x greater financial impact and improves care quality: Organizations fully leveraging Waystar's integrated clinical documentation integrity (CDI) workflows achieve an 87% increase in CDI program impact, generate $2.17 million in incremental reimbursement per 10,000 discharges, and improve Patient Safety Indicator Composite (PSI-90) scores by an average of 8.4 points, demonstrating how connected financial and clinical intelligence strengthens both reimbursement and care quality.
   
• Waystar Utilization Management increases observation-to-inpatient conversion rates by 13%, captures more revenue, and mitigates denial risk: Providers using Waystar's advanced utilization management workflows predict inpatient status within the first hour of a patient visit 82% of the time, increase observation-to-inpatient conversion rates by 13%, and reduce medical-necessity denial rates to less than 2%, demonstrating the value of real-time intelligence tied to downstream revenue outcomes.
  
  
• Waystar Anomaly Detection protects against revenue leakage before the claim is generated and unlocks up to $3 million in incremental revenue per 10,000 admissions based on early adopter results: Organizations utilizing Waystar's automated charge, coding, and documentation reviews can capture millions in additional revenue, with net rebilled dollars for coding anomalies increasing by 90% per 10,000 discharges compared with 2024 results.

The report finds that improving mid-cycle performance requires a unified, end-to-end, AI-powered platform and outlines five actionable strategies organizations can use to improve visibility, prevent revenue leakage earlier, and deliver stronger ROI.

The State of the Mid‑Revenue Cycle report is available on Waystar's website and will also be available at the 2026 HFMA Annual Conference, where Waystar will host the panel "The Path to the Autonomous Revenue Cycle: Key Components to Turn AI Promise into Reality" on June 9 at 8:10 a.m. ET at the Gaylord National Resort & Convention Center. Attendees can also visit Waystar at booth 143 throughout the conference.

About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves over 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 7.5 billion healthcare payment transactions, including over $2.4 trillion in annual gross claims and spanning approximately 60% of U.S. patients and one in three U.S. hospital discharges. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Media Contact
Kristin Lee
kristin.lee@waystar.com

Investor Contact
investors@waystar.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-research-reveals-healthcare-leaders-who-unite-financial-and-clinical-data-recover-millions-in-previously-missed-revenue-302794782.html

SOURCE Waystar

FAQ

What did Waystar (Nasdaq: WAY) reveal in its 2026 State of the Mid-Revenue Cycle report?

Waystar reported that most healthcare leaders want a single AI-powered platform linking mid-cycle and final claim. According to Waystar, 86% lack true integration, 82% struggle with rapidly changing payer policies, and 56% are unhappy with their ability to predict and prevent claim denials.

How much incremental reimbursement can Waystar (WAY) Clinical Documentation Integrity generate per 10,000 discharges?

Waystar reports its Clinical Documentation Integrity workflows can generate $2.17 million in incremental reimbursement per 10,000 discharges. According to Waystar, organizations fully leveraging integrated CDI also see 87% greater CDI program impact and average Patient Safety Indicator Composite (PSI‑90) quality score improvement of 8.4 points.

How does Waystar (WAY) utilization management affect denial rates and revenue capture?

Waystar’s utilization management helps predict inpatient status early and reduce denial risk. According to Waystar, clients predict inpatient status within the first hour in 82% of visits, increase observation-to-inpatient conversion rates by 13%, and lower medical-necessity denial rates to below 2%, supporting stronger revenue capture.

How much additional revenue can Waystar (WAY) Anomaly Detection unlock per 10,000 admissions?

Waystar indicates its Anomaly Detection can unlock up to $3 million in incremental revenue per 10,000 admissions. According to Waystar, automated charge, coding, and documentation reviews increased net rebilled dollars for coding anomalies by 90% per 10,000 discharges versus 2024 early adopter results.

Why do healthcare leaders want a single AI platform for the mid-revenue cycle, according to Waystar (WAY)?

Healthcare leaders reportedly seek one AI platform to connect clinical and financial data across the mid-cycle. According to Waystar, this unified approach can improve visibility, prevent early revenue leakage, enhance denial prevention, strengthen return on investment, and recover revenue that might otherwise be missed.

Where can investors and providers access Waystar’s 2026 State of the Mid-Revenue Cycle report?

The report is available through Waystar’s website and at the 2026 HFMA Annual Conference. According to Waystar, conference attendees can also learn more at the panel “The Path to the Autonomous Revenue Cycle” and by visiting the company’s booth 143 during the event.